
Andrea Sitlinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3463955/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kl´ inhibitor therapy. Blood, 2021, 137, 2817-2826.	1.4	38
2	Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL). Cells, 2021, 10, 1165.	4.1	7
3	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. Clinical Cancer Research, 2021, 27, 4814-4824.	7.0	23
4	Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry. Blood, 2021, 138, 2637-2637.	1.4	1
5	A pilot study of high-intensity interval training in older adults with treatment na¬ve chronic lymphocytic leukemia. Scientific Reports, 2021, 11, 23137.	3.3	9
6	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Advances, 2020, 4, 3977-3989.	5.2	55
7	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clinical Cancer Research, 2020, 26, 3589-3596.	7.0	80
8	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. Haematologica, 2020, 106, 284-287.	3.5	8
9	Impact of exercise on the immune system and outcomes in hematologic malignancies. Blood Advances, 2020, 4, 1801-1811.	5.2	32
10	A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 21-22.	1.4	8
11	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study. Blood, 2020, 136, 1-3.	1.4	0
12	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clinical Cancer Research, 2019, 25, 4264-4270.	7.0	61
13	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Advances, 2019, 3, 1568-1573.	5.2	26
14	Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer. Journal of Geriatric Oncology, 2019, 10, 317-321.	1.0	18
15	Design and Implementation of a Comprehensive Surveillance System for Venous Thromboembolism in a Defined Region Using Electronic and Manual Approaches. Applied Clinical Informatics, 2019, 10, 552-562.	1.7	6
16	Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies. Blood, 2019, 134, 502-502.	1.4	4
17	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT). Blood, 2019, 134, 4286-4286.	1.4	3
18	A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas. Blood, 2019, 134, 810-810.	1.4	9

ANDREA SITLINGER

#	Article	IF	CITATIONS
19	Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents. Blood, 2019, 134, 3321-3321.	1.4	2
20	Cancer- Associated Venous Thromboembolism (VTE) Characteristics in Blacks Compared to Whites in Durham County, North Carolina. Blood, 2019, 134, 3652-3652.	1.4	0
21	Health-Related Quality of Life. Surgical Oncology Clinics of North America, 2018, 27, 675-684.	1.5	100
22	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica, 2018, 103, 1511-1517.	3.5	135
23	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. Blood, 2018, 132, 3142-3142.	1.4	2
24	Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings. Blood, 2018, 132, 4410-4410.	1.4	0
25	Exercise and Chronic Lymphocytic Leukemia (CLL) - Relationships Among Physical Activity, Fitness, & Inflammation, and Their Impacts on CLL Patients. Blood, 2018, 132, 5540-5540.	1.4	1